GrippeEspagneV1, Main, Exploration, bibRecord, 000100

Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.

Identifieur interne : 000100 ( Main/Exploration ); précédent : 000099; suivant : 000101

Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.

Auteurs : Alin Gherasim [Espagne] ; Iván Martínez-Baz [Espagne] ; Jesús Castilla [Espagne] ; Francisco Pozo [Espagne] ; Amparo Larrauri [Espagne]

Source :

PloS one [ 1932-6203 ] ; 2017.

RBID : pubmed:28614376

Descripteurs français

KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Enfant (MeSH), Espagne (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques), Sous-type H3N2 du virus de la grippe A (effets des médicaments et des substances chimiques), Surveillance sentinelle (MeSH), Vaccins antigrippaux (pharmacologie), Vaccins antigrippaux (usage thérapeutique), Virus influenza B (effets des médicaments et des substances chimiques), Études cas-témoins (MeSH).
MESH :
- effets des médicaments et des substances chimiques : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- pharmacologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- usage thérapeutique : Vaccins antigrippaux.
- épidémiologie : Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Espagne, Femelle, Humains, Jeune adulte, Mâle, Saisons, Surveillance sentinelle, Études cas-témoins.

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Case-Control Studies (MeSH), Child (MeSH), Female (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H3N2 Subtype (drug effects), Influenza B virus (drug effects), Influenza Vaccines (pharmacology), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Seasons (MeSH), Sentinel Surveillance (MeSH), Spain (MeSH), Young Adult (MeSH).
MESH :
- chemical , pharmacology : Influenza Vaccines.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines.
- Adolescent, Adult, Case-Control Studies, Child, Female, Humans, Male, Middle Aged, Seasons, Sentinel Surveillance, Spain, Young Adult.

Abstract

BACKGROUND

Recent studies suggest that the protective effect of the current influenza vaccine could be influenced by vaccination in previous seasons. We estimated the combined effect of the previous and current influenza vaccines from the 2010-2011 season to the 2015-2016 season in Spain.

METHODS

We performed a test-negative case-control study in patients ≥9 years old. We estimated the influenza vaccine effectiveness (IVE) against influenza A(H1N1)pdm09, A(H3N2), and B virus.

RESULTS

We included 1206 influenza A(H1N1)pdm09 cases, 1358 A(H3N2) cases and 1079 B cases. IVE against A(H1N1)pdm09 virus in the pooled-season analysis was 53% (95% Confidence Interval (CI): 21% to 72%) for those vaccinated only in the current season and 50% (95%CI: 23% to 68%) for those vaccinated in the both current and previous seasons. Against the influenza A(H3N2) virus, IVE was 17% (95%CI: -43% to 52%) for those vaccinated only in the current season and 3% (95%CI: -33% to 28%) for those vaccinated in both seasons. Regarding influenza B, we obtained similar IVEs for those vaccinated only in the current and those vaccinated in both seasons: 57% (95%CI: 12% to 79%) and 56% (95%CI: 36% to 70%), respectively.

CONCLUSION

Our results suggested no interference between the previous and current influenza vaccines against A(H1N1)pdm09 and B viruses, but a possible negative interference against A(H3N2) virus.

DOI: 10.1371/journal.pone.0179160
PubMed: 28614376
PubMed Central: PMC5470701

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 00091
to stream Main, to step Curation: 000091

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.</title>
<author><name sortKey="Gherasim, Alin" sort="Gherasim, Alin" uniqKey="Gherasim A" first="Alin" last="Gherasim">Alin Gherasim</name>
<affiliation wicri:level="3"><nlm:affiliation>National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Epidemiology Centre, Carlos III Health Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona</wicri:regionArea>
<wicri:noRegion>Pamplona</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona</wicri:regionArea>
<wicri:noRegion>Pamplona</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
<affiliation wicri:level="3"><nlm:affiliation>National Centre of Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Carlos III Health Institute, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Centre of Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Carlos III Health Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name>
<affiliation wicri:level="3"><nlm:affiliation>National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Epidemiology Centre, Carlos III Health Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28614376</idno>
<idno type="pmid">28614376</idno>
<idno type="doi">10.1371/journal.pone.0179160</idno>
<idno type="pmc">PMC5470701</idno>
<idno type="wicri:Area/Main/Corpus">00091</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00091</idno>
<idno type="wicri:Area/Main/Curation">000091</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000091</idno>
<idno type="wicri:Area/Main/Exploration">000091</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.</title>
<author><name sortKey="Gherasim, Alin" sort="Gherasim, Alin" uniqKey="Gherasim A" first="Alin" last="Gherasim">Alin Gherasim</name>
<affiliation wicri:level="3"><nlm:affiliation>National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Epidemiology Centre, Carlos III Health Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona</wicri:regionArea>
<wicri:noRegion>Pamplona</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona</wicri:regionArea>
<wicri:noRegion>Pamplona</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
<affiliation wicri:level="3"><nlm:affiliation>National Centre of Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Carlos III Health Institute, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Centre of Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Carlos III Health Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name>
<affiliation wicri:level="3"><nlm:affiliation>National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Epidemiology Centre, Carlos III Health Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>Child (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H3N2 Subtype (drug effects)</term>
<term>Influenza B virus (drug effects)</term>
<term>Influenza Vaccines (pharmacology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Seasons (MeSH)</term>
<term>Sentinel Surveillance (MeSH)</term>
<term>Spain (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Espagne (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Saisons (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques)</term>
<term>Sous-type H3N2 du virus de la grippe A (effets des médicaments et des substances chimiques)</term>
<term>Surveillance sentinelle (MeSH)</term>
<term>Vaccins antigrippaux (pharmacologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Virus influenza B (effets des médicaments et des substances chimiques)</term>
<term>Études cas-témoins (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Case-Control Studies</term>
<term>Child</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Seasons</term>
<term>Sentinel Surveillance</term>
<term>Spain</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Espagne</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Saisons</term>
<term>Surveillance sentinelle</term>
<term>Études cas-témoins</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Recent studies suggest that the protective effect of the current influenza vaccine could be influenced by vaccination in previous seasons. We estimated the combined effect of the previous and current influenza vaccines from the 2010-2011 season to the 2015-2016 season in Spain.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We performed a test-negative case-control study in patients ≥9 years old. We estimated the influenza vaccine effectiveness (IVE) against influenza A(H1N1)pdm09, A(H3N2), and B virus.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>We included 1206 influenza A(H1N1)pdm09 cases, 1358 A(H3N2) cases and 1079 B cases. IVE against A(H1N1)pdm09 virus in the pooled-season analysis was 53% (95% Confidence Interval (CI): 21% to 72%) for those vaccinated only in the current season and 50% (95%CI: 23% to 68%) for those vaccinated in the both current and previous seasons. Against the influenza A(H3N2) virus, IVE was 17% (95%CI: -43% to 52%) for those vaccinated only in the current season and 3% (95%CI: -33% to 28%) for those vaccinated in both seasons. Regarding influenza B, we obtained similar IVEs for those vaccinated only in the current and those vaccinated in both seasons: 57% (95%CI: 12% to 79%) and 56% (95%CI: 36% to 70%), respectively.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Our results suggested no interference between the previous and current influenza vaccines against A(H1N1)pdm09 and B viruses, but a possible negative interference against A(H3N2) virus.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28614376</PMID>
<DateCompleted><Year>2017</Year>
<Month>09</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>12</Volume>
<Issue>6</Issue>
<PubDate><Year>2017</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.</ArticleTitle>
<Pagination><MedlinePgn>e0179160</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0179160</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies suggest that the protective effect of the current influenza vaccine could be influenced by vaccination in previous seasons. We estimated the combined effect of the previous and current influenza vaccines from the 2010-2011 season to the 2015-2016 season in Spain.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We performed a test-negative case-control study in patients ≥9 years old. We estimated the influenza vaccine effectiveness (IVE) against influenza A(H1N1)pdm09, A(H3N2), and B virus.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 1206 influenza A(H1N1)pdm09 cases, 1358 A(H3N2) cases and 1079 B cases. IVE against A(H1N1)pdm09 virus in the pooled-season analysis was 53% (95% Confidence Interval (CI): 21% to 72%) for those vaccinated only in the current season and 50% (95%CI: 23% to 68%) for those vaccinated in the both current and previous seasons. Against the influenza A(H3N2) virus, IVE was 17% (95%CI: -43% to 52%) for those vaccinated only in the current season and 3% (95%CI: -33% to 28%) for those vaccinated in both seasons. Regarding influenza B, we obtained similar IVEs for those vaccinated only in the current and those vaccinated in both seasons: 57% (95%CI: 12% to 79%) and 56% (95%CI: 36% to 70%), respectively.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggested no interference between the previous and current influenza vaccines against A(H1N1)pdm09 and B viruses, but a possible negative interference against A(H3N2) virus.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gherasim</LastName>
<ForeName>Alin</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martínez-Baz</LastName>
<ForeName>Iván</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona, Spain.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Castilla</LastName>
<ForeName>Jesús</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Instituto de Salud Pública y Laboral de Navarra, IdiSNA-Navarra Institute of Health Research, Pamplona, Spain.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pozo</LastName>
<ForeName>Francisco</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>National Centre of Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Carlos III Health Institute, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Larrauri</LastName>
<ForeName>Amparo</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-1704-2245</Identifier>
<AffiliationInfo><Affiliation>National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>cycEVA working group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>06</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>03</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>05</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>9</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28614376</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0179160</ArticleId>
<ArticleId IdType="pii">PONE-D-17-08351</ArticleId>
<ArticleId IdType="pmc">PMC5470701</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Euro Surveill. 2015 Jul 16;20(28):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26212144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015 Jan 29;20(4):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25655053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):159-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19086915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Jul 31;32(35):4404-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24968153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013 Feb 07;18(6):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23410258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2012 Mar 22;17(12):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22490308</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14001-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10570188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Apr 19;31(17):2165-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23499601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2016 Aug;16(8):942-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27061888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2017 Mar 15;215(6):847-855</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28453845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Jun 3;34(26):2926-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27038130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Apr 29;34(20):2371-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27020713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 May 15;211(10):1519-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25416812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jun 4;33(24):2813-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25936723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Oct 28;28(46):7381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20851086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Nov 15;59(10):1375-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25270645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2016;21(13):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27074657</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2011 Feb 10;16(6):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21329644</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23210147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 May 21;30(24):3595-602</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22472792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 1999 Jan 25;159(2):182-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9927102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2015;11(7):1626-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25996366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2014 Jul 1;210(1):126-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24446529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Apr 1;28(16):2903-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20153351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Enferm Infecc Microbiol Clin. 2012 Oct;30 Suppl 4:2-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23116786</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014 Mar 06;19(9):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24626206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2012 Oct;55(7):951-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22843783</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jun 26;33(29):3276-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25869892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2017 Apr 1;215(7):1059-1099</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28180277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 May 15;211(10):1529-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25406334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013 Jan 31;18(5):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23399425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Feb;58(3):319-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24235265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Sep;7(5):729-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23078073</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1997 Jul;15(10):1114-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9269055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2014 Dec;13(12):1571-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25348015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2011 Mar 17;16(11):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21435330</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Communauté de Madrid</li>
</region>
<settlement><li>Madrid</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Gherasim, Alin" sort="Gherasim, Alin" uniqKey="Gherasim A" first="Alin" last="Gherasim">Alin Gherasim</name>
</region>
<name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name>
<name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name>
<name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name>
<name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name>
<name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name>
<name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name>
<name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000100 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000100 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeEspagneV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28614376
   |texte=   Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28614376" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeEspagneV1

This area was generated with Dilib version V0.6.37.
Data generation: Fri Sep 25 11:01:38 2020. Site generation: Sat Feb 13 17:38:04 2021

	Serveur d'exploration sur la grippe en Espagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Espagne

Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.

Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki